Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
RIBOMIC Announces the Sustained Efficacy in a Long-Term Administration Trial of Umedaptanib Pegol for Achondroplasia
RIBOMIC, Apr-Jun (1Q) Ordinary Profit Loss Narrows
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2025(Based on Japanese GAAP)
[Delayed]RIBOMIC Plans to Initiate PhaseIII Clinical Trial of Umedaptanib Pegol for Achondroplasia in2026 Following the Ongoing PhaseII Clinical Trial
RIBOMIC, The Current Fiscal Year's Net Income to Widen
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
RIBOMIC, Oct-Dec (3Q) Net Income Loss Widens
Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31 2024(Based on Japanese GAAP)
RIBOMIC Inc., July-September (2Q) Net Income Loss Widens
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2024(Based on Japanese GAAP)